Our upcoming Zetta Bytes asks "Is ML the Language of Biology?", exploring breakthroughs in data-driven drug development. Don't miss out, subscribe by tomorrow: https://t.co/To0frOxzNO
Pattern Sciences will be presenting in the @ieeebigdata 2021 IEEE conference on Big Data! Our team working with the Women's Interagency HIV Study (WIHS), analyzed almost two decades of health data representing hundreds of individual patients'
Check on https://t.co/zYFLAzy4KP
The story of Maurice Hilleman, the biologist who developed over 40 vaccines, among which measles, mumps, hepatitis, chickenpox, meningitis, pneumonia: an unparalleled record of productivity that saved more lives than any other scientist of the 20th century https://t.co/aIUXPytX4B
Rob Califf has advocated for integrating real-world evidence and mobile tech into drug development and regulation -- but not for abandoning the rigor of randomization. ($) https://t.co/m6JEaarXdw
NEW COVER: 23andMe wants to make cancer drugs using insights from millions of customer DNA samples. CEO Anne Wojcicki doesn’t think that should bother anyone https://t.co/yGGkcNQsno
Pfizer says its Covid pill, used with an HIV drug, cuts the risk of hospitalization or death by 89%. Here's what you need to know. https://t.co/MuzdY7h1gk
I’m super competitive.
But in healthcare, no one company is going to solve any serious problem.
And your better-funded startup competitors are not the obstacle, status quo is.
Two dog crypto projects, Shiba Inu and Dogecoin, are worth $63 billion and basically serve no purpose.
Don’t tell me healthcare startups are overvalued. 😂